

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Wed Jun 27 16:41:08 EDT 2007

=====

Application No: 10551004 Version No: 1.0

Input Set:**Output Set:**

Started: 2007-06-27 12:08:32.799
Finished: 2007-06-27 12:08:35.197
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 398 ms
Total Warnings: 63
Total Errors: 0
No. of SeqIDs Defined: 82
Actual SeqID Count: 82

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (21)
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
W 213	Artificial or Unknown found in <213> in SEQ ID (23)
W 213	Artificial or Unknown found in <213> in SEQ ID (24)
W 213	Artificial or Unknown found in <213> in SEQ ID (27)
W 213	Artificial or Unknown found in <213> in SEQ ID (28)

Input Set:

Output Set:

Started: 2007-06-27 12:08:32.799
Finished: 2007-06-27 12:08:35.197
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 398 ms
Total Warnings: 63
Total Errors: 0
No. of SeqIDs Defined: 82
Actual SeqID Count: 82

Error code

Error Description

This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> APOGENIX Biotechnology AG

<120> Improved FC Fusion Proteins

<130> 31098PWO-HC

<140> 10551004

<141> 2007-06-27

<150> PCT/EP2004/003239

<151> 2004-03-26

<150> PCT/2004/003239

<151> 2004-03-26

<160> 82

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer
for the amplification of CD95 cDNA

<220>

<223> Sense huCD95-Hind III

<400> 1

tataaagctt gccaccatgc tgggcatctg

30

<210> 2

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer for
the amplification of CD95 cDNA

<220>

<223> Antisense huCD95-BgI II

<400> 2

tataagatct ggatccttcc tctttgc

27

<210> 3

<211> 30

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer
 for the amplification of IgG1 Fc cDNA

<220>
 <223> Sense hulgG1Fc-BgIII

<400> 3
 tataagatct tgtgacaaaa ctcacacatg 30

<210> 4
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer for
 the amplification of IgG1 Fc cDNA

<220>
 <223> Antisense hulgG1Fc-XhoI

<400> 4
 tataactcgag tcattttaccc ggagacaggg 30

<210> 5
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer for
 the changing the Kozak Sequence from GCCACCATGC to
 GCCGCCACCATGG

<220>
 <223> ShuCD95EC_altKozak

<400> 5
 tataaagctt gccgccacca tgggtgggcat c 31

<210> 6
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer
 for the changing the Kozak Sequence from
 GCCACCATGC to GCCGCCACCATGG

<220>
 <223> AS698 hulgG1Fc-XhoI

<400> 6
 tataactcgag tcatttaccc ggagacaggg 30

<210> 7
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer for
 amplifying cDNA of human IgG1 Fc (partial hinge
 CH3)

<220>
 <223> Sense_hulgG1

<400> 7
 ccagggactc ctgcctcttg tgacaaaact cacacatg 38

<210> 8
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer for
 amplifying cDNA of human IgG1 Fc (partial hinge
 CH3)

<220>
 <223> Antisense_ERIhulgG1

<400> 8
 tatagaattc tcatttaccc ggagacaggg 30

<210> 9
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer used to
 amplify the cDNA of TRAILR2 domain

<220>
 <223> Sense_HIII_TRAILR2

<400> 9
 tataaagctt gccgccacca tggaacaacg gggacagaa 40

<210> 10
 <211> 33

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer used to
 amplify the cDNA of TRAILR2 domain

 <220>
 <223> Antisense_TRAILR2

 <400> 10
 gtgagttttg tcacaagagg caggagtccc tgg 33

 <210> 11
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer for PCR
 used to utilize fragments for cloning purposes

 <220>
 <223> Sense_HIII_TRAILR2

 <400> 11
 tataaagctt gccgccacca tggaacaacg gggacagaac 40

 <210> 12
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer for
 PCR used to utilize fragments for cloning
 purposes

 <220>
 <223> Antisense_ERIhulgG1

 <400> 12
 tatagaattc tcatttaccc ggagacaggg 30

 <210> 13
 <211> 335
 <212> PRT
 <213> human

 <220>
 <223> CD95 >sp/P25445/TNR6_HUMAN Tumor necrosis factor
 receptor superfamily 6 precursor (FASL-receptor)
 (Apoptosis-mediating surface antigen FAS) (Apo-1
 antigen) (CD95) - Homo sapiens (Human)

<400> 13

Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala
1 5 10 15

Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser
20 25 30

Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn
35 40 45

Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro
50 55 60

Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro
65 70 75 80

Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His
85 90 95

Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly
100 105 110

Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr Lys Cys Arg
115 120 125

Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp
130 135 140

Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr
145 150 155 160

Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn Leu Gly Trp
165 170 175

Leu Cys Leu Leu Leu Leu Pro Ile Pro Leu Ile Val Trp Val Lys Arg
180 185 190

Lys Glu Val Gln Lys Thr Cys Arg Lys His Arg Lys Glu Asn Gln Gly
195 200 205

Ser His Glu Ser Pro Thr Leu Asn Pro Glu Thr Val Ala Ile Asn Leu
210 215 220

Ser Asp Val Asp Leu Ser Lys Tyr Ile Thr Thr Ile Ala Gly Val Met
225 230 235 240

Thr Leu Ser Gln Val Lys Gly Phe Val Arg Lys Asn Gly Val Asn Glu
245 250 255

Ala Lys Ile Asp Glu Ile Lys Asn Asp Asn Val Gln Asp Thr Ala Glu
260 265 270

Gln Lys Val Gln Leu Leu Arg Asn Trp His Gln Leu His Gly Lys Lys
275 280 285

Glu Ala Tyr Asp Thr Leu Ile Lys Asp Leu Lys Lys Ala Asn Leu Cys

290	295	300																	
Thr	Leu	Ala	Glu	Lys	Ile	Gln	Thr	Ile	Ile	Leu	Lys	Asp	Ile	Thr	Ser				
305					310					315					320				
Asp	Ser	Glu	Asn	Ser	Asn	Phe	Arg	Asn	Glu	Ile	Gln	Ser	Leu	Val					
				325					330					335					

<210> 14
 <211> 330
 <212> PRT
 <213> human

<220>
 <223> IgG1 > sp/P01857/GC1_HUMAN Ig gamma-1 chain C
 region - Homo sapiens (Human)

<400> 14

Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys				
1				5					10					15					
Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr				
			20					25					30						
Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser				
		35					40					45							
Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser				
	50					55						60							
Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr				
65					70					75					80				
Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys				
			85						90					95					
Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys				
			100					105					110						
Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro				
		115					120					125							
Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys				
		130				135					140								
Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp				
145				150					155						160				
Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu				
			165						170					175					
Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu				
			180					185					190						
His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn				

195

200

205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210215220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225230235240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245250255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260265270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275280285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290295300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305310315320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325330

<210> 15

<211> 400

<212> PRT

<213> Artificial Sequence

<220>

<221> MUTAGEN

<222> (1)..(400)

<223> CD95-Fc fusion protein (AA 1-172 CD95 and AA 102-330 IgG1)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 15

Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala
151015

Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser
202530

Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn
354045

Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro
505560

Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro
65707580

Asp	Cys	Val	Pro	Cys	Gln	Glu	Gly	Lys	Glu	Tyr	Thr	Asp	Lys	Ala	His	
				85					90					95		
Phe	Ser	Ser	Lys	Cys	Arg	Arg	Cys	Arg	Leu	Cys	Asp	Glu	Gly	His	Gly	
			100					105					110			
Leu	Glu	Val	Glu	Ile	Asn	Cys	Thr	Arg	Thr	Gln	Asn	Thr	Lys	Cys	Arg	
			115					120					125			
Cys	Lys	Pro	Asn	Phe	Phe	Cys	Asn	Ser	Thr	Val	Cys	Glu	His	Cys	Asp	
	130					135					140					
Pro	Cys	Thr	Lys	Cys	Glu	His	Gly	Ile	Ile	Lys	Glu	Cys	Thr	Leu	Thr	
145					150					155					160	
Ser	Asn	Thr	Lys	Cys	Lys	Glu	Glu	Gly	Ser	Arg	Ser	Cys	Asp	Lys	Thr	
				165					170					175		
His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	
			180					185					190			
Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	
		195					200					205				
Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	
	210					215					220					
Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	
225					230				235						240	
Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	
				245					250					255		
Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	
			260					265					270			
Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	
		275					280					285				
Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	
	290					295					300					
Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	
305					310					315					320	
Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	
				325					330					335		
Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	
			340					345					350			
Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	
		355					360					365				
Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	
	370					375						380				

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
385 390 395 400

<210> 16
<211> 43
<212> PRT
<213> human

<220>
<223> CD95 extracellular domain (AA 131-173)

<400> 16
Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys
1 5 10 15
Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr Ser Asn
20 25 30
Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn
35 40

<210> 17
<211> 22
<212> PRT
<213> human

<220>
<223> huIgG1 (AA 99-120)

<400> 17
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1 5 10 15
Pro Glu Leu Leu Gly Gly
20

<210> 18
<211> 60
<212> PRT
<213> Artificial Sequence

<220>
<223> CD95-Fc fusion protein of CD95 extracellular
domain (AA 131-173) and huIgG1 (AA99-120) with an
overlapping amino acid (CD95 AA 172 and huIgG1 AA
102)

<220>

<223> Description of Artificial Sequence: fusion
protein

<400> 18

Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys
1 5 10 15

Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr Ser Asn
20 25 30

Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Cys Asp Lys Thr His Thr
35 40 45

Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
50 55 60

<210> 19

<211> 468

<212> PRT

<213> human

<220>

<223> TRAIL-R1 >sp/000220/T10A_HUMAN Tumor necrosis
factor receptor superfamily member 10A precursor
(Death receptor 4) (TNF-related
apoptosis-including ligand receptor 1) (TRAIL
receptor-1) (TRAIL-R1)

<400> 19

Met Ala Pro Pro Pro Ala Arg Val His Leu Gly Ala Phe Leu Ala Val
1 5 10 15

Thr Pro Asn Pro Gly Ser Ala Ala Ser Gly Thr Glu Ala Ala Ala Ala
20 25 30

Thr Pro Ser Lys Val Trp Gly Ser Ser Ala Gly Arg Ile Glu Pro Arg
35 40 45

Gly Gly Gly Arg Gly Ala Leu Pro Thr Ser Met Gly Gln His Gly Pro
50 55 60

Ser Ala Arg Ala Arg Ala Gly Arg Ala Pro Gly Pro Arg Pro Ala Arg
65 70 75 80

Glu Ala Ser Pro Arg Leu Arg Val His Lys Thr Phe Lys Phe Val Val
85 90 95

Val Gly Val Leu Leu Gln Val Val Pro Ser Ser Ala Ala Thr Ile Lys
100 105 110

Leu His Asp Gln Ser Ile Gly Thr Gln Gln Trp Glu His Ser Pro Leu
115 120 125

Gly Glu Leu Cys Pro Pro Gly Ser His Arg Ser Glu His Pro Gly Ala

